TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: blood chemistry profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean of Haemagglutination Inhibiting (HI) Antibodies Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Self-perceived workability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rhinitis symptom scores change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cytokine in nasal secretion change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time From Induction of Labor Until Delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Change in experience of group leadership
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Percentage of subjects with adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of subjects with adverse events (AEs) leading to discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Socket dimensions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants who experience one or more dose-limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Concomitant presence of other CV risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Degree of Peripheral Neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reproducibility of ejection fraction measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reproducibility of myocardial strain measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: FEV1 (Forced Expiratory Volume in 1 Second)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Radial artery vasospasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: % of the prescribed cycles delivered in the specified time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: FlowOx™-induced change in arterial leg blood flow (LBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Clinician Administered Posttraumatic Stress Disorder Scale - 5 (CAPS-5)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Difference in distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean improvement of the global score of the EORTC QLQ-INFO 25
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Baseline Mean Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: changes of semen volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: changes of sperm concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: changes of sperm morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: changes of sperm motility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Total morphine utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Gestational age at the initiation of oral feeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight at discharge (g)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total length of hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Inter-rater and test-retest reliability of HHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inter-rater and test-retest reliability of E-link
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inter-rater and test-retest reliability of functional strength measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anterior opening distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Axial Length Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Readmitted Because of Drug Related Reasons
Endpoint domain: Adverse events/effects
Primary endpoint: Patient Reported Post Operative Opioid Use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Patient Reported Postoperative Pain: Visual Analogue Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with Therapy and Therapists Scale (STTS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: UCLA Loneliness Scale version 3
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time of maximum drug concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under curve from time 0 to 24h (AUC0-24h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants with a Red Blood Cell Transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: PID from Pre-dose Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective Response Rate to Selumetinib Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in atrial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Presence of atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in FDG-PET/MR SUVmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in FDG-PET/MR SUVmean
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ADCmean
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiosensitivity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fingers range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Disabilities of the Arm, Shoulder, and Hand (DASH) questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Potency as assessed by SHIM Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Return to sexual function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rate of minimal residual disease (MRD)-negative complete response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Initial Symptom Control
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Success rate of post-operative analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of prostate cancer with Gleason score ≥ 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of prostate cancer with Gleason score ≤ 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Parathyroid Hormone Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Time Required for Proper Placement of the Endobronchial Blocker
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Heart rate comparisons
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Respiratory rate comparisons
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: SpO2 measurements comparisons
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS-Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Participants Score on Pain Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in dyspnea VAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contracture of Scar Surface Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in MCC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: CIV amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Montgomery-Asberg Depression Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in the Hamilton Depression Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sensibility of the Red Flags Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attainment of analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of fusion with segmental lordosis angle increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of reintervention due to failure of initial intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Clinically Significant Adverse Events (AEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Vector Copy Number (VCN) in Peripheral Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Time Curve (AUC) of lisdexamfetamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Late Luminal Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cumulative recurrence-free rate
Endpoint domain: Mortality/survival
Primary endpoint: Clinical Global Impression-Severity, Improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Occurrences of Paralysis caused by Radiation Myelitis
Endpoint domain: Adverse events/effects
Primary endpoint: Number of adverse and serious adverse events (AEs/SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of immune response against AAV capsid
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of immune response against GAA transgene
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of stress fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Prevalence of stress fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Feasibility of delivering radiation treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: rate of grade 4 neutropenia
Endpoint domain: Adverse events/effects
Primary endpoint: Dyspnea perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Breathe-holding time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: End-tidal CO2 measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Nijmegen Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: AUC and Cmax of R and S-warfarin isomers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Local Tumor Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Average Unpleasantness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Average Pain Rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to Distract
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Rehabilitation device design evaluation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rehabilitation device functionality evaluation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tumour infiltrating lymphocytes (TILs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in BOLD contrast of the breasts and/or chest wall tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility as measured by a BOLD contrast signal in at least 30% of subjects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prognosis of acute ischemic stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: PNRS change >= 50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ODI change > 10 points
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Full Donor Chimerism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Youth sexual knowledge, attitudes, and behavior
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline Erectile Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in spasticity measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Change in Histologic Grade of Bronchial Dysplasia (Participant-specific Analysis)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Histologic Grade of Bronchial Dysplasia (Lesion-specific Analysis)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pregnancy and delivery outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Area Under the Concentration-time Curve From 0 to Infinity (AUC 0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Plasma Concentration (Cmax) of Famotidine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First phase insulin secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Glucose disappearance rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intraoperative analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in memory accuracy
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Concentration of meropenem in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference of Gastric Microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Tumor vessel identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor vessel density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with CRE decolonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of participants with an adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Complete Colonoscopy to the Cecum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Wettability of contact lenses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability measured by Recruitment Rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility measured by Sample Size
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: corneal edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Provocative Concentration (PC20)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Serum Clearance of Micafungin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Food Intake (Lunch Buffet) at 24 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Absolute Intake of Fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Absolute Intake of Carbohydrates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Absolute Intake of Sugar
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Absolute Intake of Protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants Achieving ACR20 Response at Month 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With DAS28-4 (ESR) Less Than 2.6 at Month 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variations of albumin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete remission (CR)/complete remission without recovery of counts (CRi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prehospital EEG value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Regression curve and correlation coefficient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 28 tender joints count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: 28 swollen joints count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: disease activity score of 28 joint count (DAS28)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of serum pepsinogens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change from Baseline in systolic and diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pre-fall classification performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of the NBI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal pain score on numeric rating scale (NRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Suppuration upon probing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to composite endpoint (10% decline in FVC, hospitalization, lung transplant, death)
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of subjects with treatment-emergent AEs (TEAEs) and serious AEs (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Overall Response Rate (ORR) as determined by RECIST 1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Progression Free Survival (PFS) as determined by RECIST 1.1
Endpoint domain: Mortality/survival
Primary endpoint: Success rate of intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Vaccine Effectiveness Against Genital Infection with HPV-16/18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Secretion severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharyngeal residue severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients with dose limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects' Eyes Showing Myopia Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in teachers' application of harsh discipline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in student's exposure to harsh discipline by teachers
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: percentage of patients who completed the SFST without complications
Endpoint domain: Adverse events/effects
Primary endpoint: Complex Esthetic Index (CEI)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Positive incremental post-prandial blood glucose area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Neurodevelopment at early childhood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of gene expression during childhood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UFMG Sydenham's Chorea Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect of prone position on respiratory function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Oral Streptococci levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Cholesterol Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in endothelial health
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fasting serum total cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: MSS-INV at V7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes